DOCSLIB.ORG

Comparative Effects of Cerivastatin and Fenofibrate on the Atherogenic Lipoprotein Phenotype in Proteinuric Renal Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Effects of Cerivastatin and Fenofibrate on the Atherogenic Lipoprotein Phenotype in Proteinuric Renal Disease J Am Soc Nephrol 12: 341–348, 2001 Comparative Effects of Cerivastatin and Fenofibrate on the Atherogenic Lipoprotein Phenotype in Proteinuric Renal Disease CHRISTOPHER J. DEIGHAN,*† MURIEL J. CASLAKE,† MICHAEL MCCONNELL,† J. MICHAEL BOULTON-JONES,* and CHRISTOPHER J. PACKARD† *Renal Unit and †Department of Pathological Biochemistry, Glasgow Royal Infirmary, Glasgow, United Kingdom. Abstract. Patients with nephrotic-range proteinuria have im- centration (49%), RLP-C (35%), and RLP-TG (44%; all P Ͻ paired clearance of triglyceride-rich lipoproteins. This results 0.01). Fenofibrate also reduced %LDLIII from 60 to 33% (P Ͻ in the atherogenic lipoprotein phenotype (mild hypertriglycer- 0.01). HDL-C (19%, P Ͻ 0.01) increased with fenofibrate idemia, low high-density lipoproteins [HDL], and excess treatment; LDL-C and total LDL were unchanged. The reduc- small, dense low-density lipoproteins [LDLIII]). Excess rem- tion in LDLIII concentration and RLP-C with fenofibrate treat- nant lipoproteins (RLP) are linked to hypertriglyceridemia and ment correlated with plasma triglyceride reduction (LDLIII r2 may contribute to the atherogenicity of nephrotic dyslipidemia. ϭ 67%, P Ͻ 0.001; RLP cholesterol r2 ϭ 58%, P Ͻ 0.005). A randomized crossover study compared the effects of a statin Serum creatinine increased with fenofibrate treatment (14%, P (cerivastatin) and a fibrate (fenofibrate) on LDLIII and RLP in Ͻ 0.01); however, creatinine clearance was unchanged. LD- 12 patients with nephrotic-range proteinuria. Cerivastatin re- LIII concentration was 187 Ϯ 85 mg/dl after cerivastatin duced cholesterol (21%, P Ͻ 0.01), triglyceride (14%, P Ͻ treatment and 133 Ϯ 95 mg/dl after fenofibrate treatment. 0.05), LDL cholesterol (LDL-C; 23%, P Ͻ 0.01), total LDL Cerivastatin and fenofibrate reduce LDLIII concentration in (18%, P Ͻ 0.01), and LDLIII concentration (27% P Ͻ 0.01). nephrotic-range proteinuria. However, atherogenic concentra- %LDLIII, RLP-C, and RLP triglyceride (RLP-TG) were un- tions of LDLIII remain prevalent after either treatment. Feno- changed. Plasma LDLIII reduction with cerivastatin treatment fibrate but not cerivastatin reduces remnant lipoproteins. The correlated with LDL-C reduction (r2 ϭ 34%, P Ͻ 0.05). two treatments seem to reduce LDLIII by different mecha- Fenofibrate lowered cholesterol (19%), triglyceride (41%), nisms, suggesting a potential role for combination therapy to very low-density lipoprotein cholesterol (52%), LDLIII con- optimize lowering of LDLIII and RLP. Patients with proteinuria have an increased incidence of car- and retrospective studies have demonstrated a link between diovascular disease (1). Those with nephrotic-range proteinuria LDLIII and increased risk of coronary artery disease (4,5), and experience a 5.5-fold increase in the relative risk of myocardial a plasma level of LDLIII Ͼ100 mg/dl confers a sevenfold infarction, even after correction for hypertension and smoking increase in the risk of myocardial infarction (6). We recently (2). More than two thirds of patients with nephrotic syndrome demonstrated that patients with nephrotic-range proteinuria have at least two risk factors for the development of athero- possess atherogenic quantities of LDLIII (7). Very low-density sclerosis (3), and the dyslipidemia that is prevalent in this lipoprotein (VLDL) can similarly be divided into large, light population is likely to contribute to the increased incidence of VLDL1 and smaller, denser VLDL2. VLDL1 and VLDL2 are cardiovascular disease. thought to be regulated independently. VLDL1 is increased in Lipoproteins exhibit heterogeneity. Low-density lipopro- patients with raised triglycerides (6), whereas excess VLDL2 is teins (LDL) can be divided into large, light LDLI (d 1.025 to found in patients with increased LDL cholesterol (LDL-C) (6). 1.034 g/ml) and LDLII (d 1.034 to 1.044 g/ml), and small, In nephrotic-range proteinuria, VLDL1 clearance is delayed dense LDL (LDLIII; d 1.044 to 1.063 g/ml). LDLIII is con- and VLDL2 production is increased (8). As a result, both sidered to be the most atherogenic LDL species. Prospective subfractions are found in increased quantities (8). Pharmacological lipid lowering with either hepatic 3-meth- ylglutaryl coenzyme A reductase inhibitors (statins) or fibrates Received June 29, 1999. Accepted June 18, 2000. reduces cardiovascular morbidity and mortality (9–11). How- Correspondence to Dr. Christopher J. Deighan, Consultant Physician, Re- ever, the majority of patients with coronary artery disease do nal Unit, Walton Building, Glasgow Royal Infirmary, Castle Street, Glas- not have hypercholesterolemia, and a large proportion have a gow, G4 0SF, UK. Phone: 0141-211-5049; Fax: 0141-211-4843; E-mail: [email protected] pattern of mild hypertriglyceridemia, low HDL, and excess LDLIII (12), known as the atherogenic lipoprotein phenotype 1046-6673/1202-0341 Journal of the American Society of Nephrology (6). In the normal populations, statins reduce LDLIII by low- Copyright © 2001 by the American Society of Nephrology ering all three LDL subfractions in concert (13). Fibrates 342 Journal of the American Society of Nephrology J Am Soc Nephrol 12: 341–348, 2001 promote a shift in LDL size toward larger, lighter particles, lesterol ester, phospholipid, and protein contents of all lipoproteins with or without a change in total LDL (14,15). Recent evidence were assayed, and lipoprotein concentrations were calculated as the suggests that remnants of triglyceride-rich lipoproteins may sum of these components. Three LDL subfractions (LDLI, d 1.025 to also be implicated in the pathogenesis of atherosclerosis (16). 1.034 g/ml; LDLII, d 1.034 to 1.044 g/ml; and LDLIII, d 1.044 to Elevated lipoprotein remnants (RLP) are found in patients with 1.063 g/ml) were isolated from fresh plasma by nonequilibrium den- sity gradient ultracentrifugation as described previously (21). The raised plasma triglyceride (17) and therefore may contribute to individual subfraction areas were quantified and expressed as percent- the increased cardiovascular risk of the atherogenic lipoprotein age of total LDL. The lipoprotein concentration of LDL was used to phenotype. generate individual subfraction concentrations. The cholesterol and In addition to hypercholesterolemia, raised plasma triglyc- triglyceride content of remnant lipoproteins (RLP-C, RLP-TG) was eride is well recognized in nephrotic-range proteinuria (18), measured using a diagnostic reagent kit from Japan Immunoresearch with reports of 67% (8) and 71% (3) of patients having a Laboratories (JIMRO; Takasaki, Japan). RLP were separated from plasma triglyceride greater than 2 mmol/L and 2.3 mmol/L, other lipoproteins by an immunoaffinity gel containing monoclonal respectively. Statins have been shown to reduce cholesterol antibodies to human apoB100 and human apoA1 (22). The cholesterol and LDL-C in patients with nephrotic dyslipidemia (8); how- and triglyceride contents of the unbound fraction were measured using ever, this cholesterol-lowering effect is also accompanied by enzymatic spectrophotometric assays. Apolipoproteins B, CII, CIII, plasma triglyceride reduction and increased receptor-mediated and E were analyzed from ethylenediaminetetraacetate plasma using kits purchased from Wako Pure Chemical Industries (Osaka, Japan). LDL clearance (19). LDLIII formation is a consequence of mild increases in plasma triglyceride (6), and therefore the Statistical Analyses triglyceride-lowering effect of statins may have a beneficial Statistical analysis was performed using MINITAB 11 for Win- effect not only on LDLIII concentration but also on the relative dows (Minitab Inc., State College, PA) and SPSS statistical package. proportions of each LDL subfraction and on remnant lipopro- Results are shown as means Ϯ SD. Baseline and end point data were teins. The aim of this study, therefore, was to compare the compared using repeated measures ANOVA, with the two treatment ability of a statin (cerivastatin) and a fibrate (fenofibrate) to modalities further compared using paired t test if the ANOVA showed lower levels of these atherogenic lipoproteins in patients with a significant difference. Pre- and posttreatment data were compared nephrotic-range proteinuria. A secondary aim was to assess using paired t test. Regression analysis identified significant changes in VLDL subfractions and plasma apolipoproteins to correlations. help identify mechanisms that underlie any changes. Results Materials and Methods Baseline Data Patients The diagnoses of the study population were IgA nephropathy Twelve patients (10 male, 2 female) were recruited from the (four), membranous nephropathy (three), minimal change ne- Glasgow Royal Infirmary Renal Unit. Inclusion criteria were (1) phropathy (two), mesangiocapillary glomerulonephritis (two) and biopsy-proven glomerular disease, (2) urinary albumin Ͼ1.5 g/24 h focal and segmental glomerulosclerosis (one). Baseline data ob- (equivalent to 3 g proteinuria/24 h), (3) serum creatinine Ͻ250 tained before treatment are shown in Tables 1 to 3. Values at the ␮mol/L, (4) cholesterol Ͼ6.5 mmol/L, and (5) triglyceride Ͼ1.5 beginning of each treatment phase (baseline and washout) did not mmol/L. Exclusion criteria were (1) significant deterioration in renal differ for any parameter. The median age of the study patients was function in the previous 6 mo and (2) having diseases or receiving 52 yr (range, 18 to 66). Average BP was 143/87 mmHg (nine treatment that influenced lipid profile (specifically, diabetes
Load more

Recommended publications
  • Nustendi, INN-Bempedoic Acid, Ezetimibe
    Summary of risk management plan for Nustendi (Bempedoic acid/Ezetimibe) This is a summary of the risk management plan (RMP) for Nustendi. The RMP details important risks of Nustendi, how these risks can be minimized, and how more information will be obtained about Nustendi's risks and uncertainties (missing information). Nustendi's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Nustendi should be used. This summary of the RMP for Nustendi should be read in the context of all this information, including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of Nustendi's RMP. I. The Medicine and What It Is Used For Nustendi is authorized for treatment of primary hypercholesterolemia in adults, as an adjunct to diet (see SmPC for the full indication). It contains bempedoic acid as the active substance and it is given by mouth. Further information about the evaluation of Nustendi’s benefits can be found in Nustendi’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi II. Risks Associated With the Medicine and Activities to Minimize or Further Characterize the Risks Important risks of Nustendi, together with measures to minimize such risks and the proposed studies for learning
    [Show full text]
  • Statins: Mechanism of Action and Effects
    J.Cell.Mol.Med. Vol 5, No 4, 2001 pp. 378-387 Review Statins: mechanism of action and effects Camelia Stancu, Anca Sima * "Nicolae Simionescu" Institute of Cellular Biology and Pathology, Bucharest, Romania Received: November 12, 2001; Accepted: December 5, 2001 • Introduction • Effects on • Classification of statins - cholesterol esterification and - How they are obtained its accumulation in macrophages - Liver metabolism - endothelial cell function - Physico-chemical properties - inflammatory process - Specific activity - proliferation, migration and • Mechanisms for the action of statins apoptosis of arterial smooth muscle cells - Mechanisms involving lipids - stability of the atherosclerotic plaque - Mechanisms involving intracellular - platelets activation signaling pathways - coagulation process • Beneficial effects of statins • Adverse effects of statins therapy • Conclusions Abstract The beneficial effects of statins are the result of their capacity to reduce cholesterol biosyntesis, mainly in the liver, where they are selectively distributed, as well as to the modulation of lipid metabolism, derived from their effect of inhibition upon HMG-CoA reductase. Statins have antiatherosclerotic effects, that positively correlate with the percent decrease in LDL cholesterol. In addition, they can exert antiatherosclerotic effects independently of their hypolipidemic action. Because the mevalonate metabolism generates a series of isoprenoids vital for different cellular functions, from cholesterol synthesis to the control of cell growth and differentiation, HMG-CoA reductase inhibition has beneficial pleiotropic effects. Consequently, statins reduce significantly the incidence of coronary events, both in primary and secondary prevention, being the most efficient hypolipidemic compounds that have reduced the rate of mortality in coronary patients. Independent of their hypolipidemic properties, statins interfere with events involved in bone formation and impede tumor cell growth.
    [Show full text]
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes
    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
    [Show full text]
  • Lipobay, INN-Cerivastatin
    ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES EMEA 2002 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged ANNEX I Marketing Authorisation Route of Member State Invented name Strength Pharmaceutical Form Packaging Package-size Holder administration Austria Bayer Austria Gesellschaft Lipobay 0.1 mg Film-coated tablet Oral use Blister 14, 20, 28, 30, G.m.b.H. 50, 98, 100 and Lerchenfelder Guertel 9-11 160 tablets A-1164 Wien Austria Bayer Austria Gesellschaft Lipobay 0.2 mg Film-coated tablet Oral use Blister 14, 20, 28, 30, G.m.b.H. 50, 98, 100 and Lerchenfelder Guertel 9-11 160 tablets A-1164 Wien Austria Bayer Austria Gesellschaft Lipobay 0.3 mg Film-coated tablet Oral use Blister 30 tablets G.m.b.H. Lerchenfelder Guertel 9-11 A-1164 Wien Austria Bayer Austria Gesellschaft Lipobay 0.4 mg Film-coated tablet Oral use Blister 30 tablets G.m.b.H. Lerchenfelder Guertel 9-11 A-1164 Wien Austria Bayer Austria Gesellschaft Liposterol 0.4 mg Film-coated tablet Oral use Blister 30 tablets G.m.b.H. Lerchenfelder Guertel 9-11 A-1164 Wien CPMP/811/02 1 EMEA 2002 Belgium Bayer NV Lipobay 0.1 mg Film-coated tablet Oral use Blister 14, 20, 28, 30, Louizalaan 143 50, 98, 100 and B-1050 Brussel 160 tablets Belgium Belgium Bayer NV Lipobay 0.2 mg Film-coated tablet Oral use Blister 14, 20, 28, 30, Louizalaan 143 50, 98, 100 and B-1050 Brussel 160 tablets Belgium Belgium Bayer NV Lipobay 0.3 mg Film-coated tablet Oral use Blister 14, 20, 28, 30, Louizalaan 143 50, 98, 100 and B-1050 Brussel 160 tablets Belgium Belgium Bayer NV Lipobay 0.4 mg Film-coated tablet Oral use Blister 14, 20, 28, 30, Louizalaan 143 50, 98, 100 and B-1050 Brussel 160 tablets Belgium Belgium Fournier Pharma S.A.
    [Show full text]
  • Rosuvastatin
    Rosuvastatin Rosuvastatin Systematic (IUPAC) name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan- 2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid Clinical data Trade names Crestor AHFS/Drugs.com monograph MedlinePlus a603033 Pregnancy AU: D category US: X (Contraindicated) Legal status AU: Prescription Only (S4) UK: Prescription-only (POM) US: ℞-only Routes of oral administration Pharmacokinetic data Bioavailability 20%[1] Protein binding 88%[1] Metabolism Liver (CYP2C9(major) andCYP2C19-mediated; only minimally (~10%) metabolised)[1] Biological half-life 19 hours[1] Excretion Faeces (90%)[1] Identifiers CAS Registry 287714-41-4 Number ATC code C10AA07 PubChem CID: 446157 IUPHAR/BPS 2954 DrugBank DB01098 UNII 413KH5ZJ73 KEGG D01915 ChEBI CHEBI:38545 ChEMBL CHEMBL1496 PDB ligand ID FBI (PDBe, RCSB PDB) Chemical data Formula C22H28FN3O6S Molecular mass 481.539 SMILES[show] InChI[show] (what is this?) (verify) Rosuvastatin (marketed by AstraZenecaas Crestor) 10 mg tablets Rosuvastatin, marketed as Crestor, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. Crestor is the fourth- highest selling drug in the United States, accounting for approx. $5.2 billion in sales in 2013.[2] Contents [hide] 1Medical uses 2Side effects and contraindications 3Drug interactions 4Structure 5Mechanism of action 6Pharmacokinetics 7Indications and regulation
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Rhoa Gtpase Inactivation by Statins Induces Osteosarcoma Cell Apoptosis by Inhibiting P42/P44- Mapks-Bcl-2 Signaling Independently of BMP-2 and Cell Differentiation
    Cell Death and Differentiation (2006) 13, 1845–1856 & 2006 Nature Publishing Group All rights reserved 1350-9047/06 $30.00 www.nature.com/cdd RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44- MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation O Fromigue´ 1, E Hay¨ 1, D Modrowski1, S Bouvet1, A Jacquel2, geranylgeranylpyrophosphate; HMG-CoA, 3-hydroxy 3-methyl- P Auberger2 and PJ Marie*,1 glutaryl coenzyme A; MAPKs, mitogen-activated protein kinases; PI3K, phosphoinositide 30 kinase; NO, nitric oxide; RT-PCR, 1 INSERM U606, University Paris 7, IFR 139, Lariboisie`re Hospital, 2 rue reverse transcription-polymerase chain reaction; TBST, tris Ambroise Pare´, 75475 Paris Cedex 10, France hydroxymethylaminomethane buffered saline Tween-20; WT, 2 INSERM U526, Faculty of Medicine Pasteur, Equipe labellise´e LNC, IFR 50, wild-type form; zVAD-fmk, z-Val-Ala-Asp-fluoromethylketone Nice, France * Corresponding author: PJ Marie, INSERM Unit 606, Hoˆpital Lariboisie`re, 2 rue Ambroise Pare´, 75475 Paris cedex 10, France. Tel: þ 33-1-49-95-63-89; Fax: þ 33-1-49-95-84-52; E-mail: [email protected] Introduction Osteosarcoma is the most common primary malignant bone Received 29.8.05; revised 20.12.05; accepted 20.12.05; published online 10.2.06 tumour occuring in children and young adults. Although Edited by SH Kaufmann aggressive chemotherapy has improved the prognosis of osteosarcoma patients, resistance to chemotherapy remains Abstract a major mechanism responsible for the failure of osteo- sarcoma treatment.1 Several studies have established that Osteosarcoma is the most common primary bone tumour apoptotic pathways contribute to the cytotoxic action of in young adults.
    [Show full text]
  • Familial Combined Hyperlipidemia: Current Knowledge, Perspectives
    REVISTA DE INVESTIGACIÓN CLÍNICA Contents available at PubMed www .clinicalandtranslationalinvestigation .com PERMANYER Rev Invest Clin. 2018;70:224-36 BRIEF REVIEW Familial Combined Hyperlipidemia: Current Knowledge, Perspectives, and Controversies Omar Yaxmehen Bello-Chavolla1,2, Anuar Kuri-García1, Monserratte Ríos-Ríos1, Arsenio Vargas-Vázquez1,2, Jorge Eduardo Cortés-Arroyo1,2, Gabriela Tapia-González1, Ivette Cruz-Bautista1,3,4 and Carlos Alberto Aguilar-Salinas1,3,4* 1Metabolic Diseases Research Unit and 3Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; 2MD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México; 4Tec Salud, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, N.L., México ABSTRACT Familial combined hyperlipidemia (FCHL) is the most prevalent primary dyslipidemia; however, it frequently remains undiagnosed and its precise definition is a subject of controversy. FCHL is characterized by fluctuations in serum lipid concentrations and may present as mixed hyperlipidemia, isolated hypercholesterolemia, hypertriglyceridemia, or as a normal serum lipid profile in combination with abnormally elevated levels of apolipoprotein B. FCHL is an oligogenic primary lipid disorder, which can occur due to the interaction of several contributing variants and mutations along with environmental triggers. Controversies surround- ing the relevance of identifying FCHL as a cause of isolated hypertriglyceridemia and a differential diagnosis of familial hyper- triglyceridemia are offset by the description of associations with USF1 and other genetic traits that are unique for FCHL and that are shared with other conditions with similar pathophysiological mechanisms. Patients with FCHL are at an increased risk of cardiovascular disease and mortality and have a high frequency of comorbidity with other metabolic conditions such as type 2 diabetes, non-alcoholic fatty liver disease, steatohepatitis, and the metabolic syndrome.
    [Show full text]
  • NCEP Drug Treatment
    NCEP Drug Treatment The information contained in this document is taken directly from the National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) that is published by the National Institutes of Health – National Heart, Lung and Blood Institute. Major Classes of Drugs Available Affecting Lipoprotein Metabolism HMG CoA reductase inhibitors—lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin Bile acid sequestrants—cholestyramine, colestipol, colesevelam Nicotinic acid—crystalline, timed-release preparations, Niaspan® Fibric acid derivatives (fibrates)—gemfibrozil, fenofibrate, clofibrate Estrogen replacement Omega-3 fatty acids Major Uses and Lipid/ Lipoprotien Effects of Each Drug Class Drug Class Major Use Lipid/ Lipoprotein Effects LDL ↓ 18-55% HMG CoA reductase To lower LDL cholesterol HDL ↑ 5-15% inhibitors (statins) TG ↓ 7-30% LDL ↓ 15-30% Bile acid sequestrants To lower LDL cholesterol HDL ↑ 3-5% TG No effect or increase LDL ↓ 5-25% Useful in most lipid and Nicotinic acid HDL ↑ 15-35% lipoprotein abnormalities TG ↓ 20-50% LDL ↓ 5-20% (in nonhypertriglyceridemic persons); Hypertriglyceridemia; may be increased in hypertriglyceridemic persons Fibric acids Atherogenic dyslipidemia HDL ↑ 10-35% (more in severe hypertriglyceridemia) TG ↓ 20-50% NCEP Drug Treatment The information contained in this document is taken directly from the National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) that is published by the National Institutes of Health – National Heart, Lung and
    [Show full text]
  • Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy
    1047 J Epidemiol Community Health: first published as 10.1136/jech.2003.013409 on 16 November 2004. Downloaded from RESEARCH REPORT Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases Giovanni Corrao, Antonella Zambon, Lorenza Bertu`, Edoardo Botteri, Olivia Leoni, Paolo Contiero ............................................................................................................................... J Epidemiol Community Health 2004;58:1047–1051. doi: 10.1136/jech.2003.013409 Study objective: Although lipid lowering drugs are effective in preventing morbidity and mortality from cardiovascular events, the extent of their adverse effects is not clear. This study explored the association between prescription of lipid lowering drugs and the risk of peripheral neuropathy. Design: A population based case-control study was carried out by linkage of several automated databases. Setting: Resident population of a northern Italian Province aged 40 years or more. Participants: Cases were patients discharged for peripheral neuropathy in 1998–1999. For each case up See end of article for authors’ affiliations to 20 controls were randomly selected among those eligible. Altogether 2040 case patients and 36 041 ....................... controls were included in the study. Exposure ascertainment: Prescription drug database was used to assess exposure to lipid lowering drugs Correspondence to: Professor G Corrao, at any time in the one year period preceding the index date.
    [Show full text]
  • Apolipoprotein A-I Mutations and Cardiovascular Disease Ernst J
    Apolipoprotein A-I Mutations and Cardiovascular Disease Ernst J. Schaefer, MD Distinguished University Professor Human Nutrition Research Center on Aging at Tufts University, Tufts University School of Medicine, Boston, MA & Chief Medical Officer, Boston Heart Diagnostics, Framingham, MA May 26th, 2015 ISA 2015, Amsterdam, the Netherlands Decreased HDL-C and ApoA-I Framingham Offspring Study • Hypertriglyceridemia • Obesity • Diabetes • Male gender • Sedentary lifestyle • Smoking Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF J Lipid Res. 35:871-882, 1994. Human Apolipoprotein (Apo) Metabolism Synthetic Sites Catabolic Sites FFA Chylomicron LPL, HL, LCAT Chylomicron 5 hours ApoB-48 Remnant Liver other Apos 4 ApoB-48, ApoE 6 Lipids Lipids 1 8 Kidney Intestine HDL 12 mg/kg/d ApoA-I 3 other Apos Scavenger Liver Lipids Cells 9 2 VLDL 12 mg//kg/d LDL ApoB-100 ApoB-100 Peripheral other Apos LPL, HL, 5 Lipids 3.5 days Cells Lipids LCAT 7 FFA 4 hours Schaefer & Levy New Engl J Med 1985; 312:1300, Cohn JS et al J Clin Invest 1990: 85:804, Schaefer EJ. Am J Clin Nutr. 2002;75:191 Lipoprotein Disorders in Families with Premature CHD • Familial Lipoprotein (a) Excess: 19% • Familial Dyslipidemia (High TG, Low HDL): 15% • Familial Combined Hyperlipidemia: 14% (high LDL-C &TG, usually low HDL-C) • Familial Hypoalphalipoproteinemia: 4% • Familial Hypercholesterolemia: 1% Genest JJ, Martin-Munley S, McNamara JR, Ordovas JM, Jenner J, Myers R, Wilson PW, Schaefer EJ. Circulation 85:2025-2033, 1992. (use of 10th and 90th percentile cutpoints from Framingham ApoA-I-Containing HDL Subpopulation Profiles of a Control and a CHD Patient pre pre [nm] 17.0 9.51 8.16 7.10 4.66 Asztalos et al.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]